It is estimated that 3 million people in the United States have pathogenic variations that increase the risk of heart disease and cancer. If people with such variations are identified, medical intervention and deaths are available to significantly reduce. However, the current recommendations emphasize family -based or ethnic specific standards so that they can determine the risk of examination, which can lose most of the population affected. Recently, researchers and public health professionals are considering the genomic screening of the population, or offering genetic tests to people, regardless of the personal or family history of their disease, to identify adults who can benefit from initial intervention. However, before implementing population genomic screening programs, it is helpful to get data from the cost of cost effectiveness to inform the policy and exercise decisions.
Analysis of cost effectiveness in public health genomics
- Cost effectiveness models are used to assess the economic costs of health results and interference.
- Models can compare a new health interference with previous standards of maintenance or no care.
- The effectiveness of the cost depends on the parameters included in the model, such as the cost of implementing health interference and the effect of interference on health results. Hin from the sensitivity analysis is used to understand how the variable model can affect the results in the parameters.
- For more information, please attend our October 26 Webinar on the cost of cost effectiveness in public health genomics
A recent study reviews the effectiveness of the simultaneous genomic screening cost of American adults, which includes three CDC tires 1 genomic applications, hereditary breasts and ovarian cancer, lunch syndrome, and family hypercalletium, compared to personal or personal tests. Tire 1 genomic applications are those that have a significant ability to positively affect the public health.
Study models have been considered such as age, factors such as age, spread and admission of the variety of disease -related conditions in the population, and if a variety of disease -related screening is detected, the usefulness and utility of the risk reducing the risk. The models also calculated the genetic screening panels and any results of any care costs, as well as the consequences of the inflammatory tests (genetic examination of the biological relatives of individuals associated with genetic variations).
The study shows that the population is focused on the pathogenic variations associated with hereditary breasts and ovarian cancer, lunch syndrome, and family hypercalletiums, which costs usual care in American adults under 40 years of age. This search assumes a relatively low cost for genomic screening (about $ 250 for screening tests) and that genetic risk people have access to preventive care. The model results also showed that screening at the age of 100,000 unprecedented 30 years could result in about 101 less cancer cases and 15 less cardiovascular incidence.
Challenges for the cost of cost effectiveness in public health genomics
The cost of cost effects depends on model parameters. In order to assess the authenticity of the cost effectiveness of cost, it is necessary to accurately fix, diagnose and refer to the quantity of expenses and parameters sources. Earlier in the study, various types of spreads and penetration parameters were primarily based on estimates by European lineage groups. Therefore, the results of the study cannot be well translated into populations, including non -European lineage. Models related to risk reducing interference or prevention treatment input may not properly reflect all health care experiments, especially for individuals or communities who may face economic, insurance, logistics or other obstacles to care. Other factors that affect screening costs, such as provider or genetic consultation, were not understood in detail in study models.
Population genomic screening costs are more accurate to show real -world costs, realistic model parameters are needed. Therefore, constant research on genetic variations, population genomic screening, and population and diversity in population and settings are needed.
The implications of the health of the public
Initial cost effectiveness suggests that the population related to tire 1 applications can be effective at the genomic screening cost and if applied to adults under the age of 40, screening test costs are low, and those who are found to have a variety of pathogens. Since more data is collected from screening trials about various penetrations and precision behaviors and results after screening, the cost effectiveness can lead to improved estimates about the update of parameters, impact on quality of life and overall impact on public health. Adding data from the population of multiple backgrounds and conditions will make the cost of cost more representative and promote equal implementation of population -based genomic screening.
